FDA calendar · January 2024 · built from SEC filings

PDUFA dates January 2024: FDA calendar and catalysts.

Updated Snapshot 20261116T222116ZBuilt

0 PDUFA dates fell in January 2024. The FDA calendar also recorded 39 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.

PDUFA dates in January 2024

No PDUFA dates are disclosed for this period as of November 16, 2026.

Download: CSV · JSON · iCal (next 30 days, CC BY 4.0) · Calendar API · All months

January 2024: other FDA decisions and filings

DateDrugCompanyEventIndicationStatusSource
Jan 2024Month disclosedLOQTORZI (toripalimab)CHRSFDA approval—ApprovedSEC Form 10-K
Jan 2024Month disclosedMVASI® (bevacizumab)OTLKComplete Response Letter—CRL issuedSEC Form 10-Q
Jan 2024Month disclosedZUSDURI (mitomycin)URGNNDA/BLA submission—CompletedSEC Form 10-Q
Jan 2024Month disclosedVCA-894AVNDAFDA approvalpatient with CMT2SApprovedSEC Form 10-K
Jan 2024Month disclosedVTR-297VNDAFDA approvalonychomycosis, a fungal infection of the nailApprovedSEC Form 10-K
January 5, 2024—OCSFDA approval—ApprovedSEC 8-K Exhibit 99.1
January 5, 2024ZELSUVMI (berdazimer)PTHSFDA approval—ApprovedSEC 8-K Exhibit 99.1
January 12, 2024KEYTRUDA® (pembrolizumab)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
January 12, 2024Dupixent (dupilumab)REGNLabel expansion—ApprovedopenFDA Drugs@FDA
January 18, 2024Piqray (alpelisib)NVSLabel expansion—ApprovedopenFDA Drugs@FDA
January 19, 2024Balversa (erdafitinib)JNJLabel expansion—ApprovedopenFDA Drugs@FDA
January 23, 2024ZYNRELEF® (bupivacaine-meloxicam)HRTXFDA approval—ApprovedSEC 8-K Exhibit 99.1
January 24, 2024Koselugo (selumetinib sulfate)AZNLabel expansion—ApprovedopenFDA Drugs@FDA
January 25, 2024KEYTRUDA® (pembrolizumab)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
January 25, 2024Dupixent (dupilumab)REGNLabel expansion—ApprovedopenFDA Drugs@FDA
January 26, 2024Avycaz (avibactam sodium; ceftazidime)ABBVLabel expansion—ApprovedopenFDA Drugs@FDA
January 26, 2024Opdivo® (nivolumab)BMYLabel expansion—ApprovedopenFDA Drugs@FDA
January 31, 2024Tagrisso® (osimertinib)AZNLabel expansion—ApprovedopenFDA Drugs@FDA

January 2024: dated readouts

DateDrugCompanyEventIndicationStatusSource
Jan 2024Month disclosedlepzacitinib (ATI-1777)ACRSTopline readoutmild to severe atopic dermatitisPositiveSEC Form 10-Q
Jan 2024Month disclosed—ALVOTopline readout—PositiveSEC Form 10-K
Jan 2024Month disclosedEylea®ALVOTopline readoutneovascularPositiveSEC 8-K Exhibit 99.1
Jan 2024Month disclosedPAVBLU® (aflibercept)ALVOTopline readoutneovascularPositiveSEC 8-K Exhibit 99.1
Jan 2024Month disclosedJAKAFI (ruxolitinib)INCYTopline readout—PositiveSEC Form 10-Q
Jan 2024Month disclosedihl-42x: 2.5 mg dronabinol + 125 mg acetazolamide (IHL-42X)IXHLTopline readout—PositiveSEC Form 10-Q
Jan 2024Month disclosedurcosimod (OK-101)OKYOTopline readoutDED patientsPositiveSEC 8-K Exhibit 99.1
Jan 2024Month discloseddenifanstat (TVB-2640)SGMTTopline readout—Positivesec_424b
January 8, 2024HLP004HELPTopline readout—PositiveSEC 8-K Exhibit 99.1
January 8, 2024CYB004HELPTopline readout—PositiveSEC 8-K Exhibit 99.1

January 2024: trial starts and primary completions

DateDrugCompanyEventIndicationStatusSource
Jan 2024Month disclosedKANJINTI® (trastuzumab)BNTXTrial startHER2-expressing advanced solid tumorsCompletedSEC 8-K Exhibit 99.1
Jan 2024Month disclosedonvuzosiranADRXTrial start—Completedsec_424b
Jan 2024Month disclosedELI-002ELTXTrial start—CompletedSEC Form 10-K
Jan 2024Month disclosedTagrisso® (osimertinib)GNPXTrial start—CompletedSEC Form 8-K
Jan 2024Month disclosedchikungunya (VLA1553)VALNTrial start—CompletedSEC Form 10-K
Jan 2024Month disclosedIXCHIQVALNTrial start—CompletedSEC Form 10-K
Jan 2024Month disclosedFT825FATETrial startadvanced solid tumorsCompletedSEC Form 10-K
Jan 2024Month disclosedTecentriq® (atezolizumab)GNPXTrial start—CompletedSEC Form 10-Q
Jan 2024Month disclosedOP-3136OLMATrial startER+/HER2- metastatic breast cancer and other cancersCompletedSEC Form 10-K
Jan 2024Month disclosednomlabofusp (CTI-1601)LRMRTrial start—CompletedSEC Form 10-Q
Jan 2024Month disclosedVBP301VORTrial start—CompletedSEC Form 10-K

2 more milestones are guided to a half-year or full-year window, or estimated from ClinicalTrials.gov primary completion dates, that overlaps January 2024. They are on each drug page and in the calendar API.

Questions

What PDUFA dates are in January 2024?

0 PDUFA dates fell in January 2024. The FDA calendar also recorded 39 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.

Can these dates change?

Yes. The FDA can extend a review by three months after a major amendment, and it sometimes acts before the goal date. Each row links the filing the date came from.

Built from primary public sources only: sponsor SEC filings (8-K, EX-99.1, 10-Q, 10-K), the FDA advisory committee calendar, FDA Novel Drug Approvals and Complete Response Letter records, openFDA, and ClinicalTrials.gov (U.S. National Library of Medicine). Every row links the sentence it came from. Dates move; the linked source is authoritative. Not investment or medical advice.

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.